Atomoxetine; Reboxetine/Monoamine Oxidase Inhibitors
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Both medicines effect chemical levels in the brain.
What might happen:
Taking these medicines together can result in serious side effects, including high fever, muscle stiffness, muscle spasms, agitation, confusion, coma, and death.
What you should do about this interaction:
Contact your healthcare professionals (e.g. doctor or pharmacist) right away about taking these medicines together.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Strattera (atomoxetine hydrochloride) US prescribing information. Eli Lilly and Company February, 2014.
2.Edronax (reboxetine mesylate) Australian prescribing information. Pfizer Australia Pty Ltd. September 1, 2004.
3.Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol 2007 Nov;152(6):946-51.
4.Peter C, Hongwan D, Kupfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol 2000 Jun;56(3):247-50.
5.Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc 2012 Sep-Oct; 19(5):735-43.